Lasa Supergenerics Limited has informed the Exchange regarding Board meeting held on August 05, 2025.
LASA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lasa Supergenerics' board, at a meeting held on August 5, 2025 (3:00 PM to 4:30 PM), approved the appointment of four new Non-Executive Independent Directors for a 5-year term ending August 4, 2031, subject to shareholder approval. The appointees are Mr. Ketan Bhau Songal (agro-veterinary sciences), Mr. Pravin Gadalya Lachake (poultry operations), Mr. Yogesh Hari Ughada (animal care), and Mrs. Rekha Hemant Wakh (animal nutrition) who joins as a Woman Director. Notably, all four directors are quite young (aged roughly 22-28), none hold shares in the company, and none currently serve on the boards of other listed companies. The directors' expertise in veterinary sciences, animal nutrition, and poultry aligns with the company's focus areas in animal health and agro-veterinary products.
This is a routine corporate governance update and is unlikely to move the stock price on its own. Shareholders will get to vote on confirming these appointments, and investors may want to keep an eye on whether the new independent directors bring meaningful strategic value given their youth and limited listed-company board experience so far.